Florida-based Puget Technologies has announced that its subsidiary Cannabis Biotech has initiated a research project to develop an intranasal formulation of cannabinoids, saying that the “project is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.” The company said that the project will be led by consultant Ken Morrow.
Morrow commented, “This platform will allow for an enhanced therapeutic effect while providing patients with an accurate dosing regimen and a steady rate of delivery across the mucous membrane, avoiding the gastrointestinal tract and loss of a percentage of the medicine through the liver.
The company’s announcement suggests that patients will accept cannabinoid use if the drugs are delivered intranasally, saying “the uptake of medicine via transmucosal systems is well accepted by patients. Flonase fluticasone propionate manufactured by GlaxoSmithKline, Rhinocort Aqua budesonide by AstraZeneca, and Ortrivine [sic] Adult Metered Dose by Novartis are popular medications which are commonly used in the US to treat hay fever and other allergies. The methodology is used as an anti-influenza therapy and to treat vitamin B deficiency, osteoporosis and nicotine addiction among other conditions.”
Puget Technologies President and CEO Ron Leyland said, “Modern medicine derived from cannabis is coming out of the shadows and a more varied group of patients are expected to seek out its benefits. Cannabis Biotech is poised to deliver scientifically engineered products to meet their needs.”
Read the Puget Technologies press release.
